Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonist dispensing increased 659.4% among young women and 587.5% among adolescent girls. The ...

Add Yahoo as a preferred source to see more of our stories on Google. In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet ...

For comparison, a 3.1% decrease was seen in the number with dispensation of drugs other than GLP-1 RAs. HealthDay News — For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP ...

USDA data shows snack sales holding steady in 2024, even as GLP-1 weight loss drug use rises, highlighting shifting consumer ...

Learn why experts advise against stopping and restarting GLP-1 drugs, the health risks of weight yo-yoing, and how to manage long-term weight loss safely.

GLP-1 RAs were first approved for youth with type 2 diabetes with liraglutide (Victoza) in 2019, followed by semaglutide (Wegovy) and dulaglutide (Trulicity) in 2022. Prior to these approvals, insulin ...

GLP-1 drugs such as Ozempic and Mounjaro are a revolution, not a trend. These weight loss drugs are one of the hottest markets in healthcare, and there’s been a dramatic surge in the number of ...

GLP-1RAs could substantially reduce mortality in patients with brain metastases and Type 2 diabetes. Read more.

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Eli Lilly (LLY) rated Sell/Avoid: overvaluation, slowing GLP-1 growth, Novo competition, bearish technicals and insider ...